Gates Package — page 736

From: "Collins, Francis (NIH/OD) [E]" </O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=COLLINSFR> To: "Stoffels, Paul [JJCUS]" I = 6 's_jnj.com> Ce: ) gatesfoundation.o: gatesfoundation.org>, )gatesfoundation.org" atesfoundation.org>, "Eiss, Robert (NIH/FIC) )mail.nih.gov>, "Glass, Roger (NIH/FIC) [E]" HB email nin. gov> Subject: RE: NIH, BMGF, and you Date: Sat, 20 May 2017 17:44:19 -0400 Importance: Normal Totally understand, Paul. We will follow up later. All the best, Francis From: Stoffels, Paul [JJCUS] [mailto [HO its.jnj.com] Sent: Friday, May 19, 2017 11:49 AM To: Collins, Francis (NIH/OD) [E] HE od. nih.gov> Ce: )gatesfoundation.org; gatesfoundation.org; Eiss, Robert (NIH/FIC) [E] mail.nih.gov>; Glass, Roger (NIH/FIC) [E] mail.nih.gov> Subject: Re: NIH, BMGF, and you Francis, I very much appreciate you including me in the reviews. For the moment I'm planned to be in Israel and Europe that week and it would be very challenging for me to adapt my agenda to make it on time to the US. Happy to follow up afterwards on the topics where I can support. It was nice to see you at the FNIH event. Looking forward to connecting soon, Best regards, Paul Sent from my iPad On May 14, 2017, at 8:48 AM, Collins, Francis (NIH/OD) [E] MJ od.nih.gov> wrote: Dear Paul, Over the past several years, the scientific leadership of the NIH and Bill & Melinda Gates Foundation have met annually to review progress of joint activities and plan future projects. Bill Gates will join our next meeting in person, to take place Friday, June 2, on the NIH campus in Bethesda, Maryland. Discussions will include innovations in vaccine R&D, led by Tony Fauci. Emphasis will be placed on therapeutic vaccines as well as developments in structure-based immunogen design. In addition, we will discuss new concepts in point-ofcare diagnostics, and measures to create a durable network of African sites capable of licensure standard trials, among other capacity needs. This latter topic will include requirements to enable clinical testing of CEPI priority vaccines, as